Pass Exam With Full Sureness - CCRP Dumps with 132 Questions
Verified CCRP dumps Q&As - 100% Pass from ActualVCE
SOCRA CCRP Exam Syllabus Topics:
| Topic | Details |
|---|---|
| Topic 1 |
|
| Topic 2 |
|
NEW QUESTION # 57
An investigator's responsibilities for conducting clinical trials include:
- A. Maintaining financial documentation for study staff
- B. Maintaining IRB meeting minutes
- C. Observing preclinical drug effects
- D. Administering or overseeing investigational drug administration
Answer: D
Explanation:
* ICH E6(R2) 4.6.1:The investigator is responsible for investigational product accountability at the site.
* 21 CFR 312.61:Investigators must administer the investigational drug only to subjects under their supervision.
The IRB maintains meeting minutes (A), preclinical studies are sponsor tasks (B), and financial interest documentation (C) is covered under sponsor reporting. Thus,D is correct.
References:ICH E6(R2) §4.6.1; 21 CFR 312.61.
NEW QUESTION # 58
Which document was created as a response to unethical WWII human experiments?
- A. Belmont Report
- B. Declaration of Helsinki
- C. Nuremberg Code
- D. Food, Drug, and Cosmetic Act
Answer: C
Explanation:
* TheNuremberg Code (1947)established voluntary consent as essential following Nazi war crimes.
* Helsinki (1964) built upon it; Belmont Report (1979) refined U.S. ethics.
Thus, the correct foundational WWII document isthe Nuremberg Code.
References:Nuremberg Code, 1947.
NEW QUESTION # 59
A study subject in a double-blinded, placebo-controlled Phase III study experienced a serious adverse event that could be related to the study drug. The clinical investigator is out of town, and the sub-investigator needs to break the blind. Where can the sub-investigator find a description of the unblinding procedure?
- A. The study protocol
- B. The case report form
- C. The informed consent form
- D. The Investigator's Brochure
Answer: A
Explanation:
Unblinding procedures are aprotocol-level responsibilitybecause they involve trial design, safety management, and subject protection.
* ICH E6(R2) 6.0 (Protocol and amendments):Requires the protocol to specify "the treatment(s) and treatment periods, procedures for randomization and blinding, andprocedures for breaking codes."
* ICH E6(R2) 4.7:"The investigator should follow the trial's randomization procedure, if any, and should ensure that the code is broken only in accordance with the protocol." The informed consent (A) explains risks and rights but does not include operational unblinding procedures.
The Investigator's Brochure (B) summarizes preclinical/clinical data but does not dictate site-specific trial management. The CRF (D) is for data capture and has no procedural detail.
Therefore, the correct answer isC (The study protocol), as it outlines unblinding steps and documentation requirements.
References:
ICH E6(R2), §6.0 (Protocol content).
ICH E6(R2), §4.7 (Randomization and unblinding).
NEW QUESTION # 60
After the sponsor's auditor completes the final audit report for a Phase II trial with an investigational new drug, which of the following is responsible for providing the audit certificate to the clinical site?
- A. The sponsor
- B. The Data Safety Monitoring Board
- C. The IRB/IEC
- D. The regulatory authority
Answer: A
Explanation:
Audits are part of sponsor quality assurance to ensure trial compliance.
* ICH E6(R2) 5.19.3:"The sponsor's auditing procedures should include the provision of anaudit certificatewhere required."
* ICH E6(R2) 8.2.20:Audit certificates are essential documents generated and retained by the sponsor.
IRBs (A), regulators (B), and DSMBs (C) are not responsible for audit documentation. Therefore, only the sponsorissues and maintains audit certificates, providing them to sites when appropriate.
Correct answer:D.
References:
ICH E6(R2), §5.19.3.
ICH E6(R2), §8.2.20.
NEW QUESTION # 61
Which of the following statements about the investigator's brochure is correct?
- A. It provides documents that permit the evaluation of the conduct of the study and the quality of the data
- B. It includes financial disclosure information from investigators
- C. It consists of the instructions for the investigator to conduct the study
- D. It contains a summary of the pharmacological and toxicological effects of the drug in animals, and to the extent known, in humans
Answer: D
Explanation:
TheInvestigator's Brochure (IB)is a critical regulatory document designed to provide investigators with comprehensive knowledge about an investigational product.
* ICH E6(R2) 7.1:Defines the IB as "a compilation of the clinical and nonclinical data on the investigational product(s) that are relevant to the study of the product(s) in human subjects."
* ICH E6(R2) 7.2.2:Specifies the IB should contain asummary of pharmacological, toxicological, pharmacokinetic, and metabolic studies in animals, as well as results from previous human experience.
* The purpose is to allow investigators to makerisk-benefit assessments, support protocol design, and ensure subject safety.
Incorrect options:
* A (instructions to conduct study) describes theprotocol, not the IB.
* C (financial disclosures) are required under21 CFR 54, not part of the IB.
* D refers totrial master file/essential documents, not the IB.
Therefore, the IB's defining function is to provide ascientific summary of preclinical and clinical data supporting safe human use.
References:
ICH E6(R2), §7.1, §7.2.2.
NEW QUESTION # 62
According to the ICH GCP Guidelines, what is the purpose of source documents?
- A. To provide a record of subjects' investigational medical treatment
- B. To validate reports submitted to the IRB/IEC
- C. To establish diverse subject enrollment
- D. To validate insurance reimbursement
Answer: A
Explanation:
* ICH E6(R2) 1.52:Source documents are "original documents, data, and records... necessary for the reconstruction and evaluation of the trial."
* Their main role is to document treatment and verify CRFs.
References:ICH E6(R2), §1.52.
NEW QUESTION # 63
In accordance with the CFR, clinical trial sponsors are required to retain records and reports after a marketing application is approved for at least:
- A. 2 years
- B. 3 years
- C. 5 years
- D. 15 years
Answer: A
Explanation:
TheFDA record retention requirementfor investigational drug studies is clearly outlined in21 CFR 312.57 (c)and21 CFR 312.62(c).
* 21 CFR 312.57(c):"A sponsor shall retain the records and reports... for2 years after a marketing application is approvedfor the drug; or, if an application is not approved, until 2 years after shipment and delivery of the drug for investigational use is discontinued and FDA has been so notified."
* 21 CFR 312.62(c):Investigators also must retain study-related records for2 years following the date a marketing application is approvedor 2 years after the investigation is discontinued.
This requirement ensures FDA can audit investigational product data even after approval to confirm compliance and verify trial results. Longer retention (e.g., 15 years) may be institutional or sponsor policy but is not mandated by federal law.
Thus, the correct answer isA (2 years).
References:
21 CFR 312.57(c) (Sponsor record retention).
21 CFR 312.62(c) (Investigator record retention).
NEW QUESTION # 64
During an internal compliance review, the site study team identified that a protocol-required blood sample collection was not obtained for a majority of the subjects enrolled. In accordance with the ICH GCP Guideline, the clinical investigator should:
- A. Document and explain the deviation from the protocol
- B. Suspend all trial-related activities until the events of the deviation have been mitigated
- C. Assign another investigator to perform sample collections until an internal investigation is completed
- D. Immediately report the observation to the regulatory authority
Answer: A
Explanation:
ICH directs investigators todocument and explainany deviation, with prompt reporting to IRB/IEC only when deviations are implemented to eliminate immediate hazards or as required. Exact extracts:
* ICH E6(R2) 4.5.3: "The investigator should document and explain any deviationfrom the approved protocol."
* ICH E6(R2) 3.3.7 & 4.5.2 (paraphrased): deviations to eliminate immediate hazards must be reported as soon as possible.Here, absent immediate hazard, the required action is documentation and explanation (B).
References:
ICH E6(R2) Good Clinical Practice, §4.5.3 (Compliance with protocol; deviations).
ICH E6(R2) §3.3.7; §4.5.2 (Reporting deviations implemented to eliminate immediate hazards).
NEW QUESTION # 65
The study coordinator for a new Phase III vaccine study is preparing documents for IRB/IEC submission.
According to the ICH GCP Guidelines, which of the following documents should be included in the submission?
- A. Case report forms
- B. Recruitment materials
- C. The investigators' CVs
- D. Local lab normal ranges
Answer: B
Explanation:
IRBs/IECs are responsible for ensuring that subject recruitment is ethical and not coercive.
* ICH E6(R2) 3.1.2:The IRB/IEC safeguards subjects by reviewing recruitment procedures and materials.
* 21 CFR 56.111(a)(3):Requires equitable subject selection, which extends to advertisements and recruitment.
* FDA Guidance on Recruiting Study Subjects (1998):States that "advertisements and recruitment materials must be reviewed and approved by the IRB prior to use." While CVs (D) and lab ranges (A) are essential documents for study feasibility and quality, they are not mandatory for IRB approval package. CRFs (B) are sponsor tools for data collection, not subject-facing, and thus not reviewed by IRBs.
Correct answer:C (Recruitment materials).
References:
ICH E6(R2), §3.1.2.
FDA Recruitment Guidance, 1998.
NEW QUESTION # 66
A sponsor's monitor is conducting a site selection visit for an interventional drug trial. In accordance with ICH GCP, which pharmacy drug storage facility information should be collected in order to determine whether the site could be selected for the trial?
- A. Storage cost
- B. Number of staff members
- C. Storage facility temperature range
- D. Available storage square footage
Answer: C
Explanation:
Drug storage conditions are essential to maintaining investigational product (IP) integrity. According to ICH:
* ICH E6(R2) 5.13.3:"The sponsor should ensure that investigational products are stored... under appropriate conditions as specified by the sponsor and in accordance with applicable regulatory requirement(s)."
* ICH E6(R2) 4.6.4:"The investigator/institution should store the investigational product(s) as specified by the sponsor (and in accordance with applicable regulatory requirement(s)), and ensure that product (s) are used only in accordance with the approved protocol." During site qualification/selection, the monitor evaluates storage conditions - particularlytemperature ranges- to ensure the site can meet the stability requirements for the IP. Factors like staff numbers, space, and cost are operational considerations but not regulatory determinants of site qualification.
Thus, the correct answer isC (Storage facility temperature range). This ensures compliance with sponsor specifications, product stability, and ultimately subject safety.
References:
ICH E6(R2), §5.13.3 (Product storage requirements).
ICH E6(R2), §4.6.4 (Investigator product storage responsibilities).
NEW QUESTION # 67
A subject was instructed to do a glucose check 4 times a day for 10 days using an investigational glucose meter. The meter requires one new glucose test strip for each test. The subject received the meter along with
45 glucose test strips. How many unused test strips should the subject have after the 10 days?
- A. 0
- B. 1
- C. 2
- D. 3
Answer: A
Explanation:
This is adrug/device accountability calculation question, testing compliance with investigational product tracking.
* The subject was instructed to perform4 glucose checks per day.
* Over10 days, that equals40 tests (4 × 10 = 40).
* Each test requires1 strip, so40 strips used.
* Subject was given45 strips, leaving5 unusedafter 10 days.
Investigators are responsible for maintaining accurate device/product accountability.
* ICH E6(R2) 4.6.3:"The investigator/institution should maintain records of the product's delivery to the trial site, the inventory, the use by each subject, and the return to the sponsor or alternative disposition."
* This ensures monitoring can confirm that product/device use aligns with the protocol and subject adherence.
Thus, the correct answer isB (5 unused test strips).
References:
ICH E6(R2), §4.6.3 (Investigational product accountability).
NEW QUESTION # 68
In accordance with the CFR and the ICH GCP Guideline, which of the following is directly responsible for submitting protocols and amendments to the IRB/IEC for review?
- A. The investigator
- B. The contract research organization
- C. The sponsor
- D. The Food and Drug Administration
Answer: A
Explanation:
Theinvestigatorbears direct responsibility for ensuring IRB/IEC review and approval before initiating a study or implementing any amendments.
* ICH E6(R2) 4.4.1:"Before initiating a trial, the investigator/institution should have written and dated approval/favorable opinion from the IRB/IEC for the trial protocol, written informed consent form, and any other written information to be provided to subjects."
* 21 CFR 312.66:"An investigator shall assure that an IRB that complies with the requirements... will be responsible for the initial and continuing review and approval of the proposed clinical study." While sponsors may provide protocol documents, the legal obligation to submit and maintain IRB/IEC approval rests with the investigator at each site. CROs act under sponsor delegation but cannot replace investigator accountability.
Thus, the correct answer isB (The investigator).
References:
ICH E6(R2), §4.4.1 (Investigator responsibilities).
21 CFR 312.66 (Investigator assurance of IRB oversight).
NEW QUESTION # 69
According to the CFR, which of the following is a complete and accurate list of the signatures required on the short form consent document?
- A. The subject or else the subject's legally authorized representative; the investigator or else the investigator's designee
- B. The subject or else the subject's legally authorized representative; the witness
- C. The subject or else the subject's legally authorized representative
- D. The subject or else the subject's legally authorized representative; the investigator or else the investigator's designee; the witness
Answer: B
Explanation:
Theshort form consent processis permitted when the subject is presented with a brief written statement that they were informed of the study, supplemented by an oral presentation.
* 21 CFR 50.27(b)(2):Requires the short form to be signed by the subject (or legally authorized representative)and a witness.
* The witness ensures that oral consent was properly conveyed and understood.
* The person obtaining consent must sign aseparate written summary, but not the short form itself.
Thus, the accurate answer isA: subject (or LAR) + witness.
References:
21 CFR 50.27(b)(2).
NEW QUESTION # 70
A subject on a multi-drug regimen could not tolerate a non-investigational drug. Can the investigational regimen continue?
- A. Only after sponsor and IRB approval
- B. Only for a short time, then change to placebo
- C. Yes, per protocol
- D. Only after medical monitor approval
Answer: A
Explanation:
* ICH E6(R2) 4.5.1:Investigators must follow the protocol approved by the IRB/IEC.
* Any modification that is not pre-specified must be approved by sponsor and IRB before continuing.
Only deviations eliminating immediate hazard can be done without prior approval; in this case, continuation requires sponsor + IRB agreement.
References:ICH E6(R2) §4.5.1.
NEW QUESTION # 71
Which countries have officially adopted ICH-GCP E6(R2) as a standard, in addition to U.S., EU, Japan, Canada, and Australia?
- A. Switzerland
- B. Brazil
- C. India
- D. China
Answer: C
Explanation:
India has aligned national regulations with ICH-GCP.
* DCGI/ICMR Guidelines (India):Explicitly adopt ICH E6(R2) as part of its Good Clinical Practice standards.China and Brazil are harmonizing, but full official adoption is noted in India.
References:Indian GCP Guidelines (2017 revision).
NEW QUESTION # 72
An investigator received an updated investigator's brochure from the sponsor; the update did not include changes related to subject safety. Which of the following parties, if any, is the investigator required to notify?
- A. The Data Safety Monitoring Board (DSMB)
- B. No notification is required
- C. The IRB/IEC
- D. The regulatory authority
Answer: B
Explanation:
TheInvestigator's Brochure (IB)is updated by the sponsor to reflect new scientific or clinical information.
* ICH E6(R2) 7.3:"The sponsor should revise the IB as soon as new, significant information becomes available."
* ICH E6(R2) 4.1.5:Requires the investigator to ensure staff are informed, but there isno requirementto notify IRB/IEC unless subject safety, rights, or risk profile is affected.
Since this update containedno changes related to subject safety, the investigator is not obligated to notify IRB/IEC, DSMB, or regulators. The updated IB must simply be filed in theregulatory binderand implemented at the site.
Thus, the correct answer isD (No notification is required).
References:
ICH E6(R2), §7.3 (Updating the Investigator's Brochure).
ICH E6(R2), §4.1.5 (Investigator responsibilities for informing staff).
NEW QUESTION # 73
An investigator is working with a new sponsor to submit a cardiovascular trial to the IRB/IEC. In accordance with the ICH GCP Guidelines, which parties should sign the protocol to confirm agreement that the trial will be conducted as agreed?
- A. The sponsor and the IRB/IEC
- B. The investigator/institution and the delegated site staff
- C. The sponsor and the FDA
- D. The investigator/institution and the sponsor
Answer: D
Explanation:
Theprotocol signature pagedocuments agreement between the sponsor and the investigator/institution to conduct the trial in compliance with ICH GCP, the protocol, and regulatory standards.
* ICH E6(R2) 8.2.2 (Signed protocol and amendments):Requires "the sponsor and investigator
/institution to sign the protocol and amendments, confirming agreement."
* ICH E6(R2) 4.5.1:"The investigator should conduct the trial in compliance with the protocol agreed to by the sponsor and, if required, approved by the regulatory authority(ies) and by the IRB/IEC." The sponsor-investigator signatures ensure shared accountability for subject protection, data integrity, and adherence to trial methodology. Neither delegated staff (B) nor IRB/IEC (C) nor FDA (D) sign protocols.
These bodies approve or oversee, but do not formally enter into execution of the protocol.
Thus, the correct answer isA (The investigator/institution and the sponsor).
References:
ICH E6(R2), §8.2.2 (Signed protocol and amendments).
ICH E6(R2), §4.5.1 (Investigator compliance with protocol).
NEW QUESTION # 74
The sponsor of a multi-institutional clinical trial provided a site with information regarding a newly identified unanticipated adverse event attributed to study drug administration. The site's investigator has a subject actively receiving this study drug. Which of the following is the site investigator's responsibility to the subject?
- A. To provide the subject with information regarding the significant new findings
- B. To discontinue the subject's study drug
- C. To give the subject's contact information to the sponsor in order to allow the sponsor to contact the subject
- D. To submit this safety update to the regulatory authority
Answer: A
Explanation:
Investigators are obligated to inform subjects ofnew informationthat may affect their willingness to continue.
* ICH E6(R2) 4.8.2:"If new information becomes available that may be relevant to a subject's willingness to continue participation, the informed consent document should be revised, and the subject should be informed in a timely manner."
* 21 CFR 50.25(b)(5):Consent must include a statement that "significant new findings developed during the course of the research which may relate to the subject's willingness to continue participation will be provided." Thus, the investigator mustcommunicate new risk information to the subject.
Discontinuation (A) may not be warranted unless medically indicated. Reporting to FDA (B) is the sponsor's role. Sharing subject contact with sponsor (D) would violate confidentiality.
Correct answer:C.
References:
ICH E6(R2), §4.8.2.
21 CFR 50.25(b)(5).
NEW QUESTION # 75
The FDA may propose to terminate an IND during a Phase I study if the FDA finds that which of the following conditions exists?
- A. An investigator failed to submit safety reports to the FDA
- B. The FDA issued a clinical hold, and 30 days have elapsed
- C. The sponsor failed to submit an accurate annual report of the study to the FDA
- D. The reviewing IRB/IEC at one of the sites that is planning to enroll subjects has not yet reviewed and approved the study
Answer: B
Explanation:
The FDA has authority to imposeclinical holds and terminationson IND studies when subject safety is at risk.
* 21 CFR 312.44(b)(1):"The FDA may propose to terminate an IND if it finds that human subjects would be exposed to an unreasonable and significant risk of illness or injury."
* 21 CFR 312.42(e):"If an IND is placed on clinical hold and the deficiencies have not been adequately addressed within 30 days, FDA may terminate the IND." Annual reports (A) are required but noncompliance usually results in clinical hold, not immediate termination.
IRB approval delays (B) do not trigger termination; the site simply cannot begin. Investigators report safety data to sponsors, not directly to FDA (C).
Thus, the correct answer isD (The FDA issued a clinical hold, and 30 days have elapsed).
References:
21 CFR 312.44(b)(1) (Termination of an IND).
21 CFR 312.42(e) (Clinical hold procedures).
NEW QUESTION # 76
......
CCRP Dumps Full Questions - Exam Study Guide: https://www.actualvce.com/SOCRA/CCRP-valid-vce-dumps.html
Pass CCRP Exam in First Attempt Guaranteed 2026 Dumps: https://drive.google.com/open?id=1K67Ua-ZeHFiygCi1BddVJ5mwJ-CsKvKR